Back to today’s briefing

Story perspectives

FDA Mandates MRI Scans for Alzheimer's Drug Leqembi

8/30/2025

25 5

Summary

Story summary

The FDA advises earlier brain scans for Alzheimer's patients on Leqembi to monitor brain swelling.
This recommendation comes after six deaths associated with amyloid-related imaging abnormalities (ARIA-E).
MRI scans are now mandatory between the second and third infusions of Leqembi.
Leqembi, approved in 2023, is intended to slow Alzheimer's progression.

1 of 1

Story summary

The FDA advises earlier brain scans for Alzheimer's patients on Leqembi to monitor brain swelling.
This recommendation comes after six deaths associated with amyloid-related imaging abnormalities (ARIA-E).
MRI scans are now mandatory between the second and third infusions of Leqembi.
Leqembi, approved in 2023, is intended to slow Alzheimer's progression.